CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit ...
Cytosorbents Corp ( (CTSO) ) has released its Q3 earnings. Here is a breakdown of the information Cytosorbents Corp presented to its investors.
PRINCETON, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery ...
DrugSorb™-ATR is an FDA Breakthrough Device eligible for priority review with an FDA decision anticipated in 2025PRINCETON, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation ...
PRINCETON, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery ...
CytoSorbents Corporation (NASDAQ: CTSO) and Converge Biotech, a prominent healthcare company with a strong critical care and infectious disease focus in India, are pleased to announce a new strategic ...
DrugSorb-ATR is not yet granted or approved in the U.S. or Canada. About CytoSorbents Corporation (NASDAQ: CTSO) CytoSorbents Corporation is a leader in the treatment of life-threatening ...
DrugSorb™-ATR is an FDA Breakthrough Device eligible for priority review with an FDA decision anticipated in 2025PRINCETON, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback